Researchers identified germline and somatic changes that marked low-grade and high-grade cases in adults and children with a condition called neurofibromatosis 1.
The projects are organized by the Eliminate Cancer Initiative, the National Brain Tumor Society, and the Pediatric Brain Tumor Foundation.
Investigators developed a droplet digital PCR assay targeting driver mutations and found that changes in circulating DNA were correlated with response to radiation.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
In PNAS this week: targeting recurrent IDH1 and IDH2 mutations in gliomas, silkworms genetically modified to produce spider silk, and more.
Patients whose tumors had methylated MGMT promoters were more likely to survive than those that did not after combination treatment with radiotherapy and temozolomide.
A modified poliovirus could be a promising treatment for brain cancer, according to NPR.
Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.
In Genome Biology this week: tumor-associated macrophage patterns in glioma, systems epigenomics algorithm, and more.
Many molecularly distinct subgroups emerged from a meta-analysis bringing together more than 1,000 high-grade glioma or diffuse intrinsic pontine glioma cases.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.